Current guidelines recommend intramuscular administration of epinephrine as the first-line drug for the emergency treatment of severe allergic reactions (anaphylaxis), but no randomized trial evidence supports this consensus.
Epinephrine in Severe Allergic Reactions: The European Anaphylaxis Register / Grabenhenrich, L.B., Dölle, S., Ruëff, F., Renaudin, J., Scherer, K., Pföhler, C., Treudler, R., Koehli, A., Mahler, V., Spindler, T., Lange, L., Bilò, M.B., Papadopoulos, N.G., Hourihane, J.O.B., Lang, R., Fernández-Rivas, M., Christoff, G., Cichocka-Jarosz, E., Worm, M.. - In: JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY. IN PRACTICE. - ISSN 2213-2198. - 6:6(2018), p. 1898-1906.e1. [10.1016/j.jaip.2018.02.026]
Epinephrine in Severe Allergic Reactions: The European Anaphylaxis Register
Bilò, Maria BeatriceMembro del Collaboration Group
;
2018-01-01
Abstract
Current guidelines recommend intramuscular administration of epinephrine as the first-line drug for the emergency treatment of severe allergic reactions (anaphylaxis), but no randomized trial evidence supports this consensus.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
